CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-28 | Wang Xiaodong Director | Sale 10b5-1 | −738 | $367.23 | $271K | 0 |
| 2026-09-28 | Wang Xiaodong Director | Option exercise · Share Option (Right to Buy) 10b5-1 | −403,364 | 806,715 | ||
| 2026-09-14 | BAKER BROS. ADVISORS LP Director | Option exercise | +30,768 | $36.83 | $1.1M | 761,410 |
| 2026-09-14 | BAKER BROS. ADVISORS LP Director | Option exercise | +30,768 | $36.83 | $1.1M | 8,099,179 |
| 2026-09-14 | BAKER BROS. ADVISORS LP Director | Option exercise · Non-Qualified Share Options | −30,768 | 0 | ||
| 2026-09-14 | BAKER BROS. ADVISORS LP Director | Option exercise · Non-Qualified Share Options | −30,768 | 0 | ||
| 2026-09-08 | Wang Xiaodong Director | Sale 10b5-1 | −1,181 | $345.38 | $408K | 6,079 |
| 2026-09-08 | Wang Xiaodong Director | Sale 10b5-1 | −2,841 | $346.16 | $983K | 3,238 |
| 2026-09-08 | Wang Xiaodong Director | Sale 10b5-1 | −1,517 | $347.39 | $527K | 1,721 |
| 2026-09-08 | Wang Xiaodong Director | Sale 10b5-1 | −1,721 | $348.01 | $599K | 0 |
| 2026-09-08 | Wang Xiaodong Director | Option exercise 10b5-1 | +31,027 | $36.90 | $1.1M | 31,027 |
| 2026-09-08 | Wang Xiaodong Director | Sale 10b5-1 | −7,492 | $348.31 | $2.6M | 23,535 |
| 2026-09-08 | Wang Xiaodong Director | Sale 10b5-1 | −10,688 | $349.28 | $3.7M | 12,847 |
| 2026-09-08 | Wang Xiaodong Director | Sale 10b5-1 | −6,569 | $350.27 | $2.3M | 6,278 |
| 2026-09-08 | Wang Xiaodong Director | Sale 10b5-1 | −6,278 | $351.25 | $2.2M | 0 |
| 2026-09-08 | Wang Xiaodong Director | Option exercise · Share Option (Right to Buy) 10b5-1 | −403,351 | 1,210,079 | ||
| 2026-09-01 | Ball Titus B. Principal Accounting Officer | Sale | −132 | $355.86 | $47K | 0 |
| 2026-08-25 | Wu Xiaobin President and COO | Sale 10b5-1 | −280 | $380.00 | $106K | 0 |
| 2026-08-12 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −1,980 | $354.71 | $702K | 52,912 |
| 2026-08-12 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −2,515 | $356.43 | $896K | 50,397 |
Page 3 of 71 · 1,406 trades